Emergent Biosolutions Inc (EBS) : Gsa Capital Partners Llp reduced its stake in Emergent Biosolutions Inc by 7.02% during the most recent quarter end. The investment management company now holds a total of 132,564 shares of Emergent Biosolutions Inc which is valued at $5.2 Million after selling 10,004 shares in Emergent Biosolutions Inc , the firm said in a disclosure report filed with the SEC on May 11, 2016.Emergent Biosolutions Inc makes up approximately 0.34% of Gsa Capital Partners Llp’s portfolio.
Other Hedge Funds, Including , Comerica Bank reduced its stake in EBS by selling 8,884 shares or 16.56% in the most recent quarter. The Hedge Fund company now holds 44,779 shares of EBS which is valued at $1.8 Million. Emergent Biosolutions Inc makes up approx 0.02% of Comerica Bank’s portfolio.Fiduciary Management Associates reduced its stake in EBS by selling 156,140 shares or 23.2% in the most recent quarter. The Hedge Fund company now holds 516,949 shares of EBS which is valued at $19.8 Million. Emergent Biosolutions Inc makes up approx 1.30% of Fiduciary Management Associates’s portfolio.Smith Asset Management Group Lp reduced its stake in EBS by selling 20 shares or 4.98% in the most recent quarter. The Hedge Fund company now holds 382 shares of EBS which is valued at $14,631. Farmers Merchants Investments Inc added EBS to its portfolio by purchasing 175 company shares during the most recent quarter which is valued at $6,703.Nordea Investment Management Ab reduced its stake in EBS by selling 403 shares or 9.6% in the most recent quarter. The Hedge Fund company now holds 3,797 shares of EBS which is valued at $146,260.
Emergent Biosolutions Inc opened for trading at $39.55 and hit $41.09 on the upside on Monday, eventually ending the session at $40.84, with a gain of 3.47% or 1.37 points. The heightened volatility saw the trading volume jump to 7,85,515 shares. Company has a market cap of $1,636 M.
On the company’s financial health, Emergent Biosolutions Inc reported $0.16 EPS for the quarter, beating the analyst consensus estimate by $ 0.28 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.12. The company had revenue of $111.00 million for the quarter, compared to analysts expectations of $107.57 million. The company’s revenue was up 74.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.50 EPS.
Many Wall Street Analysts have commented on Emergent Biosolutions Inc. Chardan Capital Markets Initiated Emergent Biosolutions Inc on Apr 15, 2016 to “Buy”, Price Target of the shares are set at $47.Singular Research Initiated Emergent Biosolutions Inc on Mar 28, 2016 to “Buy”, Price Target of the shares are set at $44.Emergent Biosolutions Inc was Initiated by Wells Fargo to “Outperform” on Feb 19, 2016.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Company’s two operating divisions include Biodefense and Biosciences. The Company’s Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical Biological Radiological Nuclear and Explosives) threats. The Biodefense division’s marketed products are BioThrax; BAT; Anthrasil; VIGIV and RSDL. The Biodefense division investigational stage product candidates include NuThrax PreviThrax GC-072 and other biodefense product candidates. The Biosciences division’s marketed products are WinRho SDF HepaGam B VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY ES414 and otlertuzumab.